Science Speaks Discusses Study Examining Long-Acting Injectable HIV Prevention Drug

Science Speaks: Long-acting injected HIV prevention effective and safe, HPTN 083 trial data shows
Antigone Barton, senior editor and writer at Science Speaks, discusses the results of a study assessing an investigational drug for HIV prevention. Barton notes the “injection every eight weeks has been found to be effective and safe in preventing HIV infection among men who have sex with men and transgender women who have sex with men, in data released [May 18] demonstrating a form of long-acting biomedical HIV prevention to be as effective as daily medicine taken by mouth” (5/18).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.